vs
Apellis Pharmaceuticals, Inc.（APLS）与TRICO BANCSHARES （TCBK）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是TRICO BANCSHARES 的1.8倍（$199.9M vs $109.4M），TRICO BANCSHARES 净利率更高（251.6% vs -29.5%，领先281.1%），TRICO BANCSHARES 同比增速更快（9.0% vs -5.9%），TRICO BANCSHARES 自由现金流更多（$127.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Trico Bancshares是一家总部位于美国的区域银行控股公司，旗下运营Tri Counties Bank，主要为北加利福尼亚州的个人消费者和中小企业提供存款、房贷、小微企业融资、财富管理等各类零售及商业银行服务。
APLS vs TCBK — 直观对比
营收规模更大
APLS
是对方的1.8倍
$109.4M
营收增速更快
TCBK
高出14.9%
-5.9%
净利率更高
TCBK
高出281.1%
-29.5%
自由现金流更多
TCBK
多$142.2M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $109.4M |
| 净利润 | $-59.0M | $33.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 42.6% |
| 净利率 | -29.5% | 251.6% |
| 营收同比 | -5.9% | 9.0% |
| 净利润同比 | -62.2% | 15.8% |
| 每股收益（稀释后） | $-0.40 | $1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTCBK
| Q4 25 | $199.9M | $109.4M | ||
| Q3 25 | $458.6M | $107.6M | ||
| Q2 25 | $178.5M | $103.6M | ||
| Q1 25 | $166.8M | $98.6M | ||
| Q4 24 | $212.5M | $100.4M | ||
| Q3 24 | $196.8M | $99.1M | ||
| Q2 24 | $199.7M | $97.9M | ||
| Q1 24 | $172.3M | $98.5M |
净利润APLSTCBK
| Q4 25 | $-59.0M | $33.6M | ||
| Q3 25 | $215.7M | $34.0M | ||
| Q2 25 | $-42.2M | $27.5M | ||
| Q1 25 | $-92.2M | $26.4M | ||
| Q4 24 | $-36.4M | $29.0M | ||
| Q3 24 | $-57.4M | $29.1M | ||
| Q2 24 | $-37.7M | $29.0M | ||
| Q1 24 | $-66.4M | $27.7M |
营业利润率APLSTCBK
| Q4 25 | -25.6% | 42.6% | ||
| Q3 25 | 48.7% | 43.2% | ||
| Q2 25 | -18.6% | 36.5% | ||
| Q1 25 | -50.0% | 35.8% | ||
| Q4 24 | -12.3% | 38.7% | ||
| Q3 24 | -24.0% | 39.8% | ||
| Q2 24 | -14.7% | 40.0% | ||
| Q1 24 | -36.0% | 38.3% |
净利率APLSTCBK
| Q4 25 | -29.5% | 251.6% | ||
| Q3 25 | 47.0% | 31.6% | ||
| Q2 25 | -23.6% | 26.6% | ||
| Q1 25 | -55.3% | 26.7% | ||
| Q4 24 | -17.1% | 221.4% | ||
| Q3 24 | -29.2% | 29.3% | ||
| Q2 24 | -18.9% | 29.7% | ||
| Q1 24 | -38.5% | 28.2% |
每股收益（稀释后）APLSTCBK
| Q4 25 | $-0.40 | $1.02 | ||
| Q3 25 | $1.67 | $1.04 | ||
| Q2 25 | $-0.33 | $0.84 | ||
| Q1 25 | $-0.74 | $0.80 | ||
| Q4 24 | $-0.30 | $0.88 | ||
| Q3 24 | $-0.46 | $0.88 | ||
| Q2 24 | $-0.30 | $0.87 | ||
| Q1 24 | $-0.54 | $0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $157.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $9.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTCBK
| Q4 25 | $466.2M | $157.0M | ||
| Q3 25 | $479.2M | $298.8M | ||
| Q2 25 | $370.0M | $314.3M | ||
| Q1 25 | $358.4M | $308.3M | ||
| Q4 24 | $411.3M | $145.0M | ||
| Q3 24 | $396.9M | $320.1M | ||
| Q2 24 | $360.1M | $206.6M | ||
| Q1 24 | $325.9M | $82.8M |
总债务APLSTCBK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTCBK
| Q4 25 | $370.1M | $1.3B | ||
| Q3 25 | $401.2M | $1.3B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.3B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.2B | ||
| Q1 24 | $266.7M | $1.2B |
总资产APLSTCBK
| Q4 25 | $1.1B | $9.8B | ||
| Q3 25 | $1.1B | $9.9B | ||
| Q2 25 | $821.4M | $9.9B | ||
| Q1 25 | $807.3M | $9.8B | ||
| Q4 24 | $885.1M | $9.7B | ||
| Q3 24 | $901.9M | $9.8B | ||
| Q2 24 | $904.5M | $9.7B | ||
| Q1 24 | $831.9M | $9.8B |
负债/权益比APLSTCBK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $133.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $127.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 116.9% |
| 资本支出强度资本支出/营收 | 0.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | 3.96× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $222.2M |
8季度趋势，按日历期对齐
经营现金流APLSTCBK
| Q4 25 | $-14.2M | $133.3M | ||
| Q3 25 | $108.5M | $45.1M | ||
| Q2 25 | $4.4M | $29.2M | ||
| Q1 25 | $-53.4M | $24.5M | ||
| Q4 24 | $19.4M | $109.7M | ||
| Q3 24 | $34.1M | $28.6M | ||
| Q2 24 | $-8.3M | $31.8M | ||
| Q1 24 | $-133.0M | $25.1M |
自由现金流APLSTCBK
| Q4 25 | $-14.3M | $127.9M | ||
| Q3 25 | $108.3M | $43.2M | ||
| Q2 25 | $4.4M | $28.2M | ||
| Q1 25 | $-53.4M | $22.8M | ||
| Q4 24 | $19.3M | $105.2M | ||
| Q3 24 | — | $27.3M | ||
| Q2 24 | $-8.4M | $30.8M | ||
| Q1 24 | $-133.3M | $24.1M |
自由现金流率APLSTCBK
| Q4 25 | -7.1% | 116.9% | ||
| Q3 25 | 23.6% | 40.2% | ||
| Q2 25 | 2.5% | 27.2% | ||
| Q1 25 | -32.0% | 23.1% | ||
| Q4 24 | 9.1% | 104.8% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | -4.2% | 31.5% | ||
| Q1 24 | -77.3% | 24.4% |
资本支出强度APLSTCBK
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.2% | 1.0% |
现金转化率APLSTCBK
| Q4 25 | — | 3.96× | ||
| Q3 25 | 0.50× | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TCBK
暂无分部数据
